S&P 500   4,076.11 (-0.10%)
DOW   34,384.85 (-0.59%)
QQQ   293.48 (+0.04%)
AAPL   148.34 (+0.21%)
MSFT   254.86 (-0.11%)
META   120.00 (+1.61%)
GOOGL   101.19 (+0.20%)
AMZN   95.43 (-1.15%)
TSLA   194.70 (+0.00%)
NVDA   171.29 (+1.22%)
NIO   12.14 (-5.01%)
BABA   86.26 (-1.48%)
AMD   77.11 (-0.67%)
T   19.15 (-0.67%)
MU   55.22 (-4.22%)
CGC   3.81 (+5.25%)
F   14.06 (+1.15%)
GE   85.50 (-0.55%)
DIS   98.37 (+0.51%)
AMC   8.89 (+22.96%)
PYPL   78.54 (+0.17%)
PFE   50.91 (+1.56%)
NFLX   317.75 (+4.00%)
S&P 500   4,076.11 (-0.10%)
DOW   34,384.85 (-0.59%)
QQQ   293.48 (+0.04%)
AAPL   148.34 (+0.21%)
MSFT   254.86 (-0.11%)
META   120.00 (+1.61%)
GOOGL   101.19 (+0.20%)
AMZN   95.43 (-1.15%)
TSLA   194.70 (+0.00%)
NVDA   171.29 (+1.22%)
NIO   12.14 (-5.01%)
BABA   86.26 (-1.48%)
AMD   77.11 (-0.67%)
T   19.15 (-0.67%)
MU   55.22 (-4.22%)
CGC   3.81 (+5.25%)
F   14.06 (+1.15%)
GE   85.50 (-0.55%)
DIS   98.37 (+0.51%)
AMC   8.89 (+22.96%)
PYPL   78.54 (+0.17%)
PFE   50.91 (+1.56%)
NFLX   317.75 (+4.00%)
S&P 500   4,076.11 (-0.10%)
DOW   34,384.85 (-0.59%)
QQQ   293.48 (+0.04%)
AAPL   148.34 (+0.21%)
MSFT   254.86 (-0.11%)
META   120.00 (+1.61%)
GOOGL   101.19 (+0.20%)
AMZN   95.43 (-1.15%)
TSLA   194.70 (+0.00%)
NVDA   171.29 (+1.22%)
NIO   12.14 (-5.01%)
BABA   86.26 (-1.48%)
AMD   77.11 (-0.67%)
T   19.15 (-0.67%)
MU   55.22 (-4.22%)
CGC   3.81 (+5.25%)
F   14.06 (+1.15%)
GE   85.50 (-0.55%)
DIS   98.37 (+0.51%)
AMC   8.89 (+22.96%)
PYPL   78.54 (+0.17%)
PFE   50.91 (+1.56%)
NFLX   317.75 (+4.00%)
S&P 500   4,076.11 (-0.10%)
DOW   34,384.85 (-0.59%)
QQQ   293.48 (+0.04%)
AAPL   148.34 (+0.21%)
MSFT   254.86 (-0.11%)
META   120.00 (+1.61%)
GOOGL   101.19 (+0.20%)
AMZN   95.43 (-1.15%)
TSLA   194.70 (+0.00%)
NVDA   171.29 (+1.22%)
NIO   12.14 (-5.01%)
BABA   86.26 (-1.48%)
AMD   77.11 (-0.67%)
T   19.15 (-0.67%)
MU   55.22 (-4.22%)
CGC   3.81 (+5.25%)
F   14.06 (+1.15%)
GE   85.50 (-0.55%)
DIS   98.37 (+0.51%)
AMC   8.89 (+22.96%)
PYPL   78.54 (+0.17%)
PFE   50.91 (+1.56%)
NFLX   317.75 (+4.00%)
NASDAQ:REPL

Replimune Group - REPL Stock Forecast, Price & News

$20.33
-0.14 (-0.68%)
(As of 12/1/2022 02:00 PM ET)
Add
Compare
Today's Range
$20.17
$20.77
50-Day Range
$15.78
$21.00
52-Week Range
$13.05
$30.89
Volume
1,735 shs
Average Volume
279,429 shs
Market Capitalization
$1.01 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$42.00

Replimune Group MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
102.8% Upside
$42.00 Price Target
Short Interest
Healthy
5.66% of Float Sold Short
Dividend Strength
N/A
Sustainability
-1.28
Upright™ Environmental Score
News Sentiment
0.93mentions of Replimune Group in the last 14 days
Based on 2 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Decreasing
From ($3.02) to ($3.43) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.46 out of 5 stars

Medical Sector

263rd out of 1,047 stocks

Biological Products, Except Diagnostic Industry

41st out of 173 stocks

REPL stock logo

About Replimune Group (NASDAQ:REPL) Stock

Replimune Group, Inc., a biotechnology company, develops oncolytic immuno-gene therapies to treat cancer. It uses its proprietary Immunotherapy platform to design and develop product candidates that are intended to activate the immune system against cancer. The company's lead product candidate is RP1, a selectively replicating version of herpes simplex virus 1, which is in Phase I/II clinical trials for a range of solid tumors; and that is in Phase II clinical trials for patients with cutaneous squamous cell carcinoma. It is also developing RP2, which is in Phase I clinical trials for an anti-CTLA-4 antibody-like protein in order to block the inhibition of the immune response otherwise caused by CTLA-4; and RP3 that is in Phase I clinical trials to express immune-activating proteins that stimulate T cells. Replimune Group, Inc. was founded in 2015 and is headquartered in Woburn, Massachusetts.

Receive REPL Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Replimune Group and its competitors with MarketBeat's FREE daily newsletter.

REPL Stock News Headlines

Expert Ratings for Replimune Group
Replimune: Recent Developments Strengthen Bull Thesis
Is Replimune Group (NASDAQ:REPL) Using Too Much Debt?
Replimune Group, Inc. (REPL)
Analyst Ratings for Replimune Group
Replimune Group: Q3 Earnings Insights
See More Headlines
Receive REPL Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Replimune Group and its competitors with MarketBeat's FREE daily newsletter.

REPL Company Calendar

Last Earnings
11/04/2021
Today
12/01/2022
Next Earnings (Estimated)
2/02/2023
Fiscal Year End
3/31/2023

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:REPL
Fax
N/A
Employees
152
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$42.00
High Stock Price Forecast
$52.00
Low Stock Price Forecast
$30.00
Forecasted Upside/Downside
+106.6%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
6 Analysts

Profitability

Net Income
$-118,040,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$7.72 per share

Miscellaneous

Free Float
37,901,000
Market Cap
$1.01 billion
Optionable
Not Optionable
Beta
1.86

Key Executives

  • Mr. Philip Astley-Sparke FSA (Age 51)
    CEO & Director
    Comp: $880.5k
  • Dr. Robert Coffin Ph.D. (Age 57)
    Founder, Pres, Chief R&D Officer and Director
    Comp: $785.89k
  • Ms. Tanya N. Lewis M.S. (Age 51)
    Chief Devel. Operations Officer
    Comp: $4.7k
  • Mr. Sushil Patel Ph.D. (Age 51)
    Chief Commercial Officer
    Comp: $594.58k
  • Ms. Jean M. Franchi (Age 56)
    Principal Accounting Officer, CFO, Treasurer, Sec. & Compliance Officer
  • Dr. Colin A. Love Ph.D. (Age 64)
    Chief Operating Officer
  • Dr. Pamela Esposito Ph.D. (Age 47)
    Chief Bus. Officer













REPL Stock - Frequently Asked Questions

Should I buy or sell Replimune Group stock right now?

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Replimune Group in the last twelve months. There are currently 6 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" REPL shares.
View REPL analyst ratings
or view top-rated stocks.

What is Replimune Group's stock price forecast for 2023?

6 Wall Street analysts have issued 12-month price objectives for Replimune Group's shares. Their REPL share price forecasts range from $30.00 to $52.00. On average, they predict the company's stock price to reach $42.00 in the next year. This suggests a possible upside of 104.5% from the stock's current price.
View analysts price targets for REPL
or view top-rated stocks among Wall Street analysts.

How have REPL shares performed in 2022?

Replimune Group's stock was trading at $27.10 on January 1st, 2022. Since then, REPL shares have decreased by 24.2% and is now trading at $20.54.
View the best growth stocks for 2022 here
.

When is Replimune Group's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, February 2nd 2023.
View our REPL earnings forecast
.

How were Replimune Group's earnings last quarter?

Replimune Group, Inc. (NASDAQ:REPL) released its quarterly earnings data on Thursday, November, 4th. The company reported ($0.56) earnings per share for the quarter, missing the consensus estimate of ($0.51) by $0.05.

What other stocks do shareholders of Replimune Group own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Replimune Group investors own include Peabody Energy (BTU), Myovant Sciences (MYOV), Peabody Energy (BTUUQ), AVEO Pharmaceuticals (AVEO), Fate Therapeutics (FATE), Immunomedics (IMMU), Pfizer (PFE), SCYNEXIS (SCYX), Exelixis (EXEL) and Fulcrum Therapeutics (FULC).

When did Replimune Group IPO?

(REPL) raised $100 million in an initial public offering (IPO) on Friday, July 20th 2018. The company issued 6,700,000 shares at a price of $14.00-$16.00 per share. J.P. Morgan, Leerink Partners and BMO Capital Markets acted as the underwriters for the IPO.

What is Replimune Group's stock symbol?

Replimune Group trades on the NASDAQ under the ticker symbol "REPL."

Who are Replimune Group's major shareholders?

Replimune Group's stock is owned by a variety of retail and institutional investors. Top institutional investors include Price T Rowe Associates Inc. MD (8.39%), Atlas Venture Life Science Advisors LLC (6.25%), BlackRock Inc. (5.56%), Vanguard Group Inc. (3.72%), State Street Corp (2.92%) and Emerald Advisers LLC (2.31%). Insiders that own company stock include Colin Love, Fund Iv LP Omega, Jason P Rhodes, Jean M Franchi, Pamela Esposito, Philip Astley-Sparke and Robert Coffin.
View institutional ownership trends
.

How do I buy shares of Replimune Group?

Shares of REPL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Replimune Group's stock price today?

One share of REPL stock can currently be purchased for approximately $20.54.

How much money does Replimune Group make?

Replimune Group (NASDAQ:REPL) has a market capitalization of $1.02 billion. The company earns $-118,040,000.00 in net income (profit) each year or ($2.74) on an earnings per share basis.

How many employees does Replimune Group have?

The company employs 152 workers across the globe.

How can I contact Replimune Group?

Replimune Group's mailing address is 500 Unicorn Park, WOBURN MA, 01801. The official website for the company is www.replimune.com. The company can be reached via phone at (781) 222-9600 or via email at ir@replimune.com.

This page (NASDAQ:REPL) was last updated on 12/1/2022 by MarketBeat.com Staff